Submitted: 10 Apr 2023
Accepted: 05 Jun 2023
ePublished: 19 Jun 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Ren Endocrinol. 2023;9: e25099.
doi: 10.34172/jre.2023.25099
  Abstract View: 600
  PDF Download: 114


Contrast-induced nephropathy; an update on pathophysiology

Yasaman Yadollahi Fars 1 ORCID logo, Razieh Moghadasi 1 ORCID logo, Shokouh Shayanpour 2* ORCID logo

1 Independent Researcher, Isfahan, Iran
2 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: Shokouh Shayanpour, Email; shayanpour-sh@ajums.ac.ir, , Email: dr.shayanpour@yahoo.com


Contrast-induced nephropathy (CIN) is a well-known complication of contrast media administration for diagnostic and therapeutic purposes. The incidence of CIN has increased with the widespread use of diagnostic imaging and contrast media. CIN is a pathological condition that typically occurs within 48 hours of exposure to contrast material and results in an increase in serum creatinine levels of more than 44 µmol/L (0.5 mg/dL) or 25% above baseline or an increase in serum creatinine of more than 1.5 times the baseline level within 7 days of exposure to contrast material or a reduction in urine output to less than 0.5 mL/h for at least 6 hours after exposure to contrast material. The mechanism of CIN is not fully understood, but it is thought to involve direct nephrotoxic effects of contrast particles, hemodynamic changes, hypoxia and oxidative stress, apoptosis, inflammation, and immune responses. Prevention of CIN involves identifying the risk factors and taking appropriate measures to mitigate them. Currently, there is no definitive treatment for CIN, and treatment is mainly symptomatic, with supportive care being the mainstay. Experimental treatments such as renal replacement therapy, extracorporeal blood purification, and stem cell therapy are being investigated, but their clinical efficacy is yet to be established.

Citation: Yadollahi Fars Y, Moghadasi R, Shayanpour S. Contrast-induced nephropathy; an update on pathophysiology. J Ren Endocrinol. 2023;9:e25099. doi: 10.34172/jre.2023.25099.
First Name
Last Name
Email Address
Security code

Abstract View: 601

Your browser does not support the canvas element.

PDF Download: 114

Your browser does not support the canvas element.